The litigation, Robbins v. Grail, Inc., alleges that the company and its executives violated the Securities Exchange Act by misleading shareholders regarding the prospects of its NHS-Galleri trial. Grail, which specializes in multi-cancer early detection, claimed its technology could significantly reduce late-stage cancer diagnoses. However, the complaint asserts that management downplayed negative internal data and ignored signs that the study’s three-year window was insufficient to reach its primary endpoint.

On February 19, 2026, the company disclosed that the trial failed to observe a statistically significant reduction in stage III-IV cancers, citing a need for longer follow-up times. The revelation triggered a sharp market reaction, causing Grail’s share price to plummet by more than 50%. Robbins Geller Rudman & Dowd LLP, the firm representing the plaintiffs, is now inviting investors with significant losses to participate in the legal proceedings.